Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2000 Oct;55(10):864–866. doi: 10.1136/thorax.55.10.864

Adult height and cryptogenic fibrosing alveolitis: a case-control study using the UK General Practice Research Database

R Hubbard 1, A Venn 1
PMCID: PMC1745612  PMID: 10992540

Abstract

BACKGROUND—The reasons why cryptogenic fibrosing alveolitis has emerged as a new clinical entity during the second half of the 20th century are unclear. Some environmental exposures have been identified as potential risk factors including occupational dust, cigarette smoking and antidepressants, but there have been no studies of the role of early life exposures. Since adult height reflects, in part, early life experience, we have examined the relation between adult height and the risk of cryptogenic fibrosing alveolitis.
METHODS—A case-control study of 569 cases and 3669 age, sex, and community matched controls drawn from the UK General Practice Research Database was undertaken.
RESULTS—Evidence was found of an inverse association between quintile of height and cryptogenic fibrosing alveolitis (odds ratio (OR) per increase in height quintile 0.93, 95% CI 0.86 to 0.99). This association was not diminished by adjustment for smoking status (OR 0.93, 95% CI 0.87 to 1.00), but some minor attenuation did occur after adjustment for oral corticosteroid use (OR 0.94, 95% CI 0.88 to 1.02). There was a significant interaction with sex such that the effect of height was strong in women (OR 0.85, 95% CI 0.75 to 0.97) and absent in men (OR 1.00, 95% CI 0.91 to 1.09).
CONCLUSIONS—These findings raise the possibility that early life exposures may be important in determining the lifetime risk of developing cryptogenic fibrosing alveolitis.



Full Text

The Full Text of this article is available as a PDF (83.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumgartner K. B., Samet J. M., Stidley C. A., Colby T. V., Waldron J. A. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997 Jan;155(1):242–248. doi: 10.1164/ajrccm.155.1.9001319. [DOI] [PubMed] [Google Scholar]
  2. Becklake M. R., Toyota B., Stewart M., Hanson R., Hanley J. Lung structure as a risk factor in adverse pulmonary responses to asbestos exposure. A case-referent study in Quebec chrysotile miners and millers. Am Rev Respir Dis. 1983 Sep;128(3):385–388. doi: 10.1164/arrd.1983.128.3.385. [DOI] [PubMed] [Google Scholar]
  3. Hubbard R., Johnston I., Coultas D. B., Britton J. Mortality rates from cryptogenic fibrosing alveolitis in seven countries. Thorax. 1996 Jul;51(7):711–716. doi: 10.1136/thx.51.7.711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hubbard R., Lewis S., Richards K., Johnston I., Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet. 1996 Feb 3;347(8997):284–289. doi: 10.1016/s0140-6736(96)90465-1. [DOI] [PubMed] [Google Scholar]
  5. Hubbard R., Venn A., Lewis S., Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000 Jan;161(1):5–8. doi: 10.1164/ajrccm.161.1.9906062. [DOI] [PubMed] [Google Scholar]
  6. Hubbard R., Venn A., Smith C., Cooper M., Johnston I., Britton J. Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis: a case-control study. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):743–747. doi: 10.1164/ajrccm.157.3.9701093. [DOI] [PubMed] [Google Scholar]
  7. Iwai K., Mori T., Yamada N., Yamaguchi M., Hosoda Y. Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med. 1994 Sep;150(3):670–675. doi: 10.1164/ajrccm.150.3.8087336. [DOI] [PubMed] [Google Scholar]
  8. Jeffrey P. K. The development of large and small airways. Am J Respir Crit Care Med. 1998 May;157(5 Pt 2):S174–S180. doi: 10.1164/ajrccm.157.5.rsaa-1. [DOI] [PubMed] [Google Scholar]
  9. Jenkins S. C., Moxham J. The effects of mild obesity on lung function. Respir Med. 1991 Jul;85(4):309–311. doi: 10.1016/s0954-6111(06)80102-2. [DOI] [PubMed] [Google Scholar]
  10. Johnston I., Britton J., Kinnear W., Logan R. Rising mortality from cryptogenic fibrosing alveolitis. BMJ. 1990 Nov 3;301(6759):1017–1021. doi: 10.1136/bmj.301.6759.1017. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Leon D. A., Smith G. D., Shipley M., Strachan D. Adult height and mortality in London: early life, socioeconomic confounding, or shrinkage? J Epidemiol Community Health. 1995 Feb;49(1):5–9. doi: 10.1136/jech.49.1.5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Palmer J. R., Rosenberg L., Shapiro S. Stature and the risk of myocardial infarction in women. Am J Epidemiol. 1990 Jul;132(1):27–32. doi: 10.1093/oxfordjournals.aje.a115639. [DOI] [PubMed] [Google Scholar]
  13. Scott J., Johnston I., Britton J. What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ. 1990 Nov 3;301(6759):1015–1017. doi: 10.1136/bmj.301.6759.1015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Shaheen S. O., Sterne J. A., Montgomery S. M., Azima H. Birth weight, body mass index and asthma in young adults. Thorax. 1999 May;54(5):396–402. doi: 10.1136/thx.54.5.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Walley T., Mantgani A. The UK General Practice Research Database. Lancet. 1997 Oct 11;350(9084):1097–1099. doi: 10.1016/S0140-6736(97)04248-7. [DOI] [PubMed] [Google Scholar]
  16. Yarnell J. W., Limb E. S., Layzell J. M., Baker I. A. Height: a risk marker for ischaemic heart disease: prospective results from the Caerphilly and Speedwell Heart Disease Studies. Eur Heart J. 1992 Dec;13(12):1602–1605. doi: 10.1093/oxfordjournals.eurheartj.a060111. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES